Manufacturer rebates to Medicare Part D plans for diabetes therapies could be reduced by 8 percent if coverage of "substantially" all drugs in that category were required, according to a study commissioned by the Academy of Managed Care Pharmacy
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
